Mesothelioma Cancer Centers
University of Michigan
Doctors Affiliated with this Treatment Facility
The University of Michigan treats cancer patients, including those with mesothelioma, at the Rogel Cancer Center. Mesothelioma is treated through their Thoracic Oncology Program, which is also where they conduct research in an effort to find more effective treatments.
Within this program is a team of thoracic surgeons, medical oncologists, radiation oncologists, pulmonologists, gastroenterologists, radiologists, pathologists and nurses. The multidisciplinary team works to provide each patient with a personalized treatment plan, consisting commonly of surgery, radiation and chemotherapy.
Rogel Cancer Center also practices the use of heated intraperitoneal chemotherapy (HIPEC), a heated chemotherapy wash, in the treatment of peritoneal mesothelioma. For patients interested in experimental treatments for mesothelioma, clinical trials are offered through the University of Michigan Cancer Center for those who are eligible.
If patients choose to receive care from UM Rogel Cancer Center, they can utilize a variety of resources. There is a patient assistance center that helps families with everything from exploring financial assistance options to lodging and parking. They also offer complementary therapies to help patients on their treatment journey, including art therapy and guided imagery therapy.
- Lung cancer
- Peritoneal mesothelioma
- Pleural mesothelioma
- Blue Distinction Center for Complex and Rare Cancers designation
- Commission on Cancer of the American College of Surgeons accreditation
- Joint Commission accreditation
- Michigan Cancer Consortium member
- National Cancer Institute Comprehensive Cancer Center designation
- National Comprehensive Cancer Network member
- Oncology Care Model designation
- The Quality Oncology Practice Initiative recognition
Mesothelioma Clinical Trials at University of Michigan
The following clinical trials are in progress or actively recruiting participants at University of Michigan:
Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin
Conditions: Advanced Malignant Solid Neoplasm; Advanced Peritoneal Malignant Mesothelioma; Advanced Pleural Malignant Mesothelioma; Recurrent Peritoneal Malignant Mesothelioma; Recurrent Pleural Malignant Mesothelioma; Refractory Malignant Solid Neoplasm; Unresectable Solid Neoplasm Last Updated: May 6, 2019 Status: Recruiting
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
Conditions: Advanced Malignancies Last Updated: April 26, 2019 Status: Active, not recruiting
Conditions: Recurrent Pleural Malignant Mesothelioma; Stage IV Pleural Mesothelioma Last Updated: February 11, 2019 Status: Active, not recruiting
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
Conditions: Epithelioid Mesothelioma; Pleural Malignant Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatoid Mesothelioma Last Updated: January 16, 2019 Status: Active, not recruiting
Conditions: Pancreatic Cancer; Thyroid Cancer; Lung Cancer; Esophageal Cancer; Thymus Cancer; Colon Cancer; Rectal Cancer; GIST; Anal Cancer; Bile Duct Cancer; Duodenal Cancer; Gallbladder Cancer; Gastric Cancer; Liver Cancer; Small Intestine Cancer; Peritoneal Surface Malignancies; Familial Adenomatous Polyposis; Lynch Syndrome; Bladder Cancer; Kidney Cancer; Penile Cancer; Prostate Cancer; Testicular Cancer; Ureter Cancer; Urethral Cancer; Hypopharyngeal Cancer; Laryngeal Cancer; Lip Cancer; Oral Cavity Cancer; Nasopharyngeal Cancer; Oropharyngeal Cancer; Paranasal Sinus Cancer; Nasal Cavity Cancer; Salivary Gland Cancer; Skin Cancer; CNS Tumor; CNS Cancer; Mesothelioma; Breastcancer; Leukemia; Melanoma; Sarcoma; Unknown Primary Tumor; Multiple Myeloma; Ovarian Cancer; Endometrial Cancer; Vaginal Cancer Last Updated: November 1, 2018 Status: Recruiting
Author: Linda Molinari
Editor in Chief, Mesothelioma Cancer AllianceRead about Linda
Reviewer: Annette Charlevois
Patient Support CoordinatorRead about Annette